206 related articles for article (PubMed ID: 8143932)
1. Effects of transforming growth factor beta (TGF beta) and 1,25 dihydroxyvitamin D3 on the function, cytochemistry and morphology of normal human osteoblast-like cells.
Ingram RT; Bonde SK; Riggs BL; Fitzpatrick LA
Differentiation; 1994 Jan; 55(2):153-63. PubMed ID: 8143932
[TBL] [Abstract][Full Text] [Related]
2. 1,25-dihydroxyvitamin D3-mediated transforming growth factor-beta release is impaired in cultured osteoblasts from patients with multiple pituitary hormone deficiencies.
Sterck JG; Klein-Nulend J; Burger EH; Lips P
J Bone Miner Res; 1996 Mar; 11(3):367-76. PubMed ID: 8852947
[TBL] [Abstract][Full Text] [Related]
3. Regulation of osteocalcin production and bone resorption by 1,25-dihydroxyvitamin D3 in mouse long bones: interaction with the bone-derived growth factors TGF-beta and IGF-I.
Staal A; Geertsma-Kleinekoort WM; Van Den Bemd GJ; Buurman CJ; Birkenhäger JC; Pols HA; Van Leeuwen JP
J Bone Miner Res; 1998 Jan; 13(1):36-43. PubMed ID: 9443788
[TBL] [Abstract][Full Text] [Related]
4. Production and action of transforming growth factor-beta in human osteoblast cultures: dependence on cell differentiation and modulation by calcitriol.
Kassem M; Kveiborg M; Eriksen EF
Eur J Clin Invest; 2000 May; 30(5):429-37. PubMed ID: 10809903
[TBL] [Abstract][Full Text] [Related]
5. Maturation state determines the response of osteogenic cells to surface roughness and 1,25-dihydroxyvitamin D3.
Lohmann CH; Bonewald LF; Sisk MA; Sylvia VL; Cochran DL; Dean DD; Boyan BD; Schwartz Z
J Bone Miner Res; 2000 Jun; 15(6):1169-80. PubMed ID: 10841186
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor beta-induced dissociation between vitamin D receptor level and 1,25-dihydroxyvitamin D3 action in osteoblast-like cells.
Staal A; Birkenhäger JC; Pols HA; Buurman CJ; Vink-van Wijngaarden T; Kleinekoort WM; van den Bemd GJ; van Leeuwen JP
Bone Miner; 1994 Jul; 26(1):27-42. PubMed ID: 7950503
[TBL] [Abstract][Full Text] [Related]
7. Anabolic effects of 1,25-dihydroxyvitamin D3 on osteoblasts are enhanced by vascular endothelial growth factor produced by osteoblasts and by growth factors produced by endothelial cells.
Wang DS; Miura M; Demura H; Sato K
Endocrinology; 1997 Jul; 138(7):2953-62. PubMed ID: 9202240
[TBL] [Abstract][Full Text] [Related]
8. 1,25-dihydroxyvitamin D3 potentiates fluoride-stimulated collagen type I production in cultures of human bone marrow stromal osteoblast-like cells.
Kassem M; Mosekilde L; Eriksen EF
J Bone Miner Res; 1993 Dec; 8(12):1453-8. PubMed ID: 8304046
[TBL] [Abstract][Full Text] [Related]
9. 1 alpha,25-Dihydroxyvitamin D3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells.
Wu Y; Haugen JD; Zinsmeister AR; Kumar R
Biochem Biophys Res Commun; 1997 Oct; 239(3):734-9. PubMed ID: 9367838
[TBL] [Abstract][Full Text] [Related]
10. 1,25 dihydroxyvitamin-D3 attenuates the confluence-dependent differences in the osteoblast characteristic proteins alkaline phosphatase, procollagen I peptide, and osteocalcin.
Siggelkow H; Schulz H; Kaesler S; Benzler K; Atkinson MJ; Hüfner M
Calcif Tissue Int; 1999 May; 64(5):414-21. PubMed ID: 10203418
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of matrix vesicle enzyme activity in osteoblast-like cells by 1,25(OH)2D3 and transforming growth factor beta (TGF beta).
Bonewald LF; Schwartz Z; Swain LD; Boyan BD
Bone Miner; 1992 May; 17(2):139-44. PubMed ID: 1611299
[TBL] [Abstract][Full Text] [Related]
12. 1,25-Dihydroxyvitamin D3 pretreatment limits prostaglandin biosynthesis by cytokine-stimulated adult human osteoblast-like cells.
Keeting PE; Li CH; Whipkey DL; Thweatt R; Xu J; Murty M; Blaha JD; Graeber GM
J Cell Biochem; 1998 Feb; 68(2):237-46. PubMed ID: 9443079
[TBL] [Abstract][Full Text] [Related]
13. Regulation of osteoblast growth by interactions between transforming growth factor-beta and 1alpha,25-dihydroxyvitamin D3.
Gurlek A; Kumar R
Crit Rev Eukaryot Gene Expr; 2001; 11(4):299-317. PubMed ID: 12067069
[TBL] [Abstract][Full Text] [Related]
14. Differentiation of heterogeneous phenotypes in human osteoblast cultures in response to 1,25-dihydroxyvitamin D3.
Thavarajah M; Evans DB; Kanis JA
Bone; 1993; 14(5):763-7. PubMed ID: 7505605
[TBL] [Abstract][Full Text] [Related]
15. Effects of methotrexate on human osteoblasts in vitro: modulation by 1,25-dihydroxyvitamin D3.
Scheven BA; van der Veen MJ; Damen CA; Lafeber FP; Van Rijn HJ; Bijlsma JW; Duursma SA
J Bone Miner Res; 1995 Jun; 10(6):874-80. PubMed ID: 7572311
[TBL] [Abstract][Full Text] [Related]
16. Titanium surface roughness alters responsiveness of MG63 osteoblast-like cells to 1 alpha,25-(OH)2D3.
Boyan BD; Batzer R; Kieswetter K; Liu Y; Cochran DL; Szmuckler-Moncler S; Dean DD; Schwartz Z
J Biomed Mater Res; 1998 Jan; 39(1):77-85. PubMed ID: 9429099
[TBL] [Abstract][Full Text] [Related]
17. [Effects of various growth factors and hormones on clonal rat pulp cells].
Liang RF
Meikai Daigaku Shigaku Zasshi; 1990; 19(1):1-20. PubMed ID: 2134279
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of normal human bone cells by transforming growth factor-beta and 1,25(OH)2 vitamin D3.
Wergedal JE; Matsuyama T; Strong DD
Metabolism; 1992 Jan; 41(1):42-8. PubMed ID: 1538645
[TBL] [Abstract][Full Text] [Related]
19. Treatment of resting zone chondrocytes with transforming growth factor-beta 1 induces differentiation into a phenotype characteristic of growth zone chondrocytes by downregulating responsiveness to 24,25-(OH)2D3 and upregulating responsiveness to 1,25-(OH)2D3.
Schwartz Z; Sylvia VL; Liu Y; Dean DD; Boyan BD
Bone; 1998 Nov; 23(5):465-70. PubMed ID: 9823454
[TBL] [Abstract][Full Text] [Related]
20. Actions of calcipotriol (MC 903), a novel vitamin D3 analog, on human bone-derived cells: comparison with 1,25-dihydroxyvitamin D3.
Evans DB; Thavarajah M; Binderup L; Kanis JA
J Bone Miner Res; 1991 Dec; 6(12):1307-15. PubMed ID: 1792941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
